Synthesis of Biphenyl Proteomimetics as Estrogen Receptor-α Coactivator Binding Inhibitors
摘要:
A novel series of biphenyl proteomimetic compounds were designed as estrogen receptor-alpha (ER alpha) coactivator binding Inhibitors. Synthesis was accomplished through a convergent approach, employing Suzuki coupling chemistry to ligate the Individual modular units. Initial biological results support the ability of these compounds to compete for the ER alpha coactivator binding groove.
Synthesis of Biphenyl Proteomimetics as Estrogen Receptor-α Coactivator Binding Inhibitors
摘要:
A novel series of biphenyl proteomimetic compounds were designed as estrogen receptor-alpha (ER alpha) coactivator binding Inhibitors. Synthesis was accomplished through a convergent approach, employing Suzuki coupling chemistry to ligate the Individual modular units. Initial biological results support the ability of these compounds to compete for the ER alpha coactivator binding groove.
[EN] MODULATORS OF NUCLEAR RECEPTOR CO-REGULATORY PROTEIN BINDING<br/>[FR] MODULATEURS DE LIAISON PROTÉINIQUE DE CORÉGULATION DE RÉCEPTEUR NUCLÉAIRE
申请人:UNIV NORTHEASTERN
公开号:WO2009117739A1
公开(公告)日:2009-09-24
Disclosed are novel compounds and compositions for inhibition of androgen and estrogen receptor signaling, methods for inhibiting androgen signaling, methods for inhibiting estrogen signaling, methods for inhibiting the interaction between a co-regulatory protein and an androgen or estrogen receptor, and methods for treating cancer.
Synthesis of Biphenyl Proteomimetics as Estrogen Receptor-α Coactivator Binding Inhibitors
作者:Anna B. Williams、Patrick T. Weiser、Robert N. Hanson、Jillian R. Gunther、John A. Katzenellenbogen
DOI:10.1021/ol901999f
日期:2009.12.3
A novel series of biphenyl proteomimetic compounds were designed as estrogen receptor-alpha (ER alpha) coactivator binding Inhibitors. Synthesis was accomplished through a convergent approach, employing Suzuki coupling chemistry to ligate the Individual modular units. Initial biological results support the ability of these compounds to compete for the ER alpha coactivator binding groove.